CN113924096A - 低剂量三联组合制剂 - Google Patents

低剂量三联组合制剂 Download PDF

Info

Publication number
CN113924096A
CN113924096A CN202080038969.1A CN202080038969A CN113924096A CN 113924096 A CN113924096 A CN 113924096A CN 202080038969 A CN202080038969 A CN 202080038969A CN 113924096 A CN113924096 A CN 113924096A
Authority
CN
China
Prior art keywords
dose
pharmaceutical composition
inhibitor
metformin
minimum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080038969.1A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬·麦克马洪
安东尼·罗杰斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
George Institute for Global Health
Original Assignee
George Institute for Global Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Institute for Global Health filed Critical George Institute for Global Health
Priority to CN202411820468.5A priority Critical patent/CN119607213A/zh
Publication of CN113924096A publication Critical patent/CN113924096A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080038969.1A 2019-03-25 2020-03-25 低剂量三联组合制剂 Pending CN113924096A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411820468.5A CN119607213A (zh) 2019-03-25 2020-03-25 低剂量三联组合制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/364,063 2019-03-25
US16/364,063 US11033544B2 (en) 2019-03-25 2019-03-25 Low-dose triple combination formulation
PCT/IB2020/000214 WO2020194052A1 (en) 2019-03-25 2020-03-25 Low-dose triple combination formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411820468.5A Division CN119607213A (zh) 2019-03-25 2020-03-25 低剂量三联组合制剂

Publications (1)

Publication Number Publication Date
CN113924096A true CN113924096A (zh) 2022-01-11

Family

ID=72606637

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080038969.1A Pending CN113924096A (zh) 2019-03-25 2020-03-25 低剂量三联组合制剂
CN202411820468.5A Pending CN119607213A (zh) 2019-03-25 2020-03-25 低剂量三联组合制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411820468.5A Pending CN119607213A (zh) 2019-03-25 2020-03-25 低剂量三联组合制剂

Country Status (11)

Country Link
US (5) US11033544B2 (https=)
EP (1) EP3946344A4 (https=)
JP (1) JP7586830B2 (https=)
KR (1) KR20220004027A (https=)
CN (2) CN113924096A (https=)
AU (2) AU2020247542A1 (https=)
BR (1) BR112021018994A2 (https=)
CA (1) CA3134800A1 (https=)
MX (2) MX2021011746A (https=)
TW (2) TW202102209A (https=)
WO (1) WO2020194052A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation
KR102853692B1 (ko) * 2021-07-08 2025-09-02 한미약품 주식회사 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제
EP4415723A4 (en) * 2021-10-12 2025-09-03 Unison Pharmaceuticals Pvt Ltd PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND EMPAGLIFLOZIN
TR2023001202A1 (tr) * 2023-02-02 2024-08-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇lm kapli empagliflozin ve metformin hi̇droklorür tabletleri̇
KR20260000968A (ko) * 2024-06-26 2026-01-05 주식회사 종근당 제2형 당뇨병 치료용 조성물, 조합물 및 병용 요법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307577A (zh) * 2009-02-13 2012-01-04 贝林格尔.英格海姆国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
WO2015173584A1 (en) * 2014-05-16 2015-11-19 Astrazeneca Ab Method for suppressing glucagon secretion of an sglt2 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
US20160067217A1 (en) * 2014-09-09 2016-03-10 ARKAY Therapeutics, LLC Metabolic syndrome treatment
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307577A (zh) * 2009-02-13 2012-01-04 贝林格尔.英格海姆国际有限公司 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
WO2015173584A1 (en) * 2014-05-16 2015-11-19 Astrazeneca Ab Method for suppressing glucagon secretion of an sglt2 inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JABBOUR SA等: "Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study", DIABETES CARE, vol. 37, no. 3, pages 740, XP002742649, DOI: 10.2337/dc13-0467 *

Also Published As

Publication number Publication date
JP7586830B2 (ja) 2024-11-19
US20220226317A1 (en) 2022-07-21
MX2021011746A (es) 2021-10-22
US20200306246A1 (en) 2020-10-01
CN119607213A (zh) 2025-03-14
US20220226315A1 (en) 2022-07-21
US20220226316A1 (en) 2022-07-21
WO2020194052A1 (en) 2020-10-01
KR20220004027A (ko) 2022-01-11
MX2024013504A (es) 2024-12-06
EP3946344A4 (en) 2022-12-28
TW202545526A (zh) 2025-12-01
CA3134800A1 (en) 2020-10-01
TW202102209A (zh) 2021-01-16
AU2020247542A1 (en) 2021-11-11
EP3946344A1 (en) 2022-02-09
US11033544B2 (en) 2021-06-15
BR112021018994A2 (pt) 2022-02-08
JP2022529208A (ja) 2022-06-20
US20210260056A1 (en) 2021-08-26
AU2025226705A1 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
CN113924096A (zh) 低剂量三联组合制剂
TWI278312B (en) Pharmaceutical composition for treating diabetes or a disease or condition associated with diabetes
CN113905738A (zh) 低剂量三联组合制剂
CN104349790A (zh) 用于治疗糖尿病的葡萄糖激酶活化剂组合物
TW200838503A (en) Pharmaceutical composition
KR100709528B1 (ko) 혈당콘트롤용 의약조성물
CA2563325C (en) Oral modified-release lozenges and their preparation method
HK40124034A (zh) 低剂量三联组合制剂
JP5117230B2 (ja) ２型糖尿病治療用の併用医薬
HK40067275A (zh) 低剂量三联组合制剂
HK40067219A (zh) 低剂量三联组合制剂
RU2359677C2 (ru) Оральные таблетки с модифицированным высвобождением и способ их получения
WO2024173747A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes
WO2026052001A1 (zh) Glp-1r激动剂与恩格列净的药物组合物及用途
EP4574148A1 (en) Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension
JPWO2004002474A1 (ja) 糖尿病性合併症の予防又は進展阻止用医薬組成物
HK1080411A (en) Drug composition for blood sugar control
HK1080381A (en) Drug composition for prevention or inhibition of advance of diabetic complication
HK1102424B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
HK1102422B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40067275

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20220111

RJ01 Rejection of invention patent application after publication